Xeris Biopharma Holdings Inc reports results for the quarter ended December 31 - Earnings Summary

Xeris Biopharma Holdings

06/03/2025 14:32

Xeris Biopharma Holdings Inc XERS.OQ reported a quarterly adjusted loss of 3 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -10 cents.  The mean expectation of six analysts for the quarter was for a loss of 6 cents per share. Wall Street expected results to range from -10 cents to -2 cents per share.

Revenue rose 35.4% to $60.10 million from a year ago; analysts expected $58.10 million.

Xeris Biopharma Holdings Inc's reported EPS for the quarter was a loss of 3 cents​.

The company reported a quarterly loss of $5.11 million.

Xeris Biopharma Holdings Inc shares had risen by 11.2% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 17.4% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the pharmaceuticals peer group is  "buy."

Wall Street's median 12-month price target for Xeris Biopharma Holdings Inc is $5.00

This summary was machine generated from LSEG data March 6 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.06
-0.03
Beat
Sep. 30 2024
-0.09
-0.11
Missed
Jun. 30 2024
-0.11
-0.10
Beat
Mar. 31 2024
-0.12
-0.14
Missed